Can metformin cause cancer
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Can Metformin Cause Cancer?
Introduction to Metformin and Cancer Risk
Metformin, a widely prescribed medication for type 2 diabetes, has been extensively studied for its potential effects on cancer. While some studies suggest that metformin may have protective effects against certain types of cancer, the evidence is mixed and warrants a closer examination.
Metformin and Cancer Incidence
General Cancer Incidence
Several studies have investigated the relationship between metformin use and overall cancer incidence. A systematic review and meta-analysis found that metformin use was associated with a 31% reduction in overall cancer risk among diabetic patients compared to other antidiabetic drugs. Another meta-analysis reported a significant reduction in the risk of all-cancer incidence with a pooled risk ratio of 0.67. However, randomized controlled trials (RCTs) did not show a significant difference in cancer risk between metformin users and non-users .
Site-Specific Cancer Incidence
Pancreatic and Liver Cancer
Strong evidence supports the association between metformin use and a decreased incidence of pancreatic and liver cancers. Multiple studies have shown a significant reduction in the risk of these cancers among metformin users .
Colorectal Cancer
The evidence for colorectal cancer is also suggestive, with studies indicating a reduced incidence and improved overall survival among metformin users .
Breast Cancer
The relationship between metformin and breast cancer is less clear. While preclinical data suggested potential benefits, observational studies have not consistently shown a significant reduction in breast cancer incidence among metformin users . However, some studies did find a reduction in all-cause mortality among breast cancer patients using metformin.
Metformin and Cancer Mortality
Overall Cancer Mortality
Metformin use has been associated with a significant reduction in cancer-related mortality in observational studies. A meta-analysis reported a pooled risk ratio of 0.66 for cancer mortality among metformin users. Another review found a significant association between metformin use and reduced cancer death risk. However, RCTs did not show a significant effect on all-cause mortality.
Specific Cancers
Lung Cancer
Preliminary studies suggest that metformin may improve survival in lung cancer patients, particularly those who are overweight or obese. Ongoing trials are investigating the potential of metformin as a chemopreventive agent in high-risk individuals.
Brain Tumors
Recent studies have explored the potential of metformin in improving outcomes for brain tumor patients. While some evidence suggests that metformin may enhance overall survival and progression-free survival when combined with standard therapies, further clinical testing is needed.
Mechanisms of Action
Metformin's potential anticancer effects are thought to be mediated through several mechanisms, including the activation of AMP-activated protein kinase (AMPK), inhibition of the mammalian target of rapamycin (mTOR), and reduction of insulin and insulin-like growth factor-1 levels. These pathways may contribute to its antitumorigenic properties.
Conclusion
The current body of evidence suggests that metformin is more likely to be associated with a reduced risk of certain cancers rather than causing cancer. While observational studies indicate potential protective effects, particularly for pancreatic, liver, and colorectal cancers, the results from randomized controlled trials are less conclusive. Further research, including long-term RCTs, is needed to confirm these findings and fully understand the role of metformin in cancer prevention and treatment.
Sources and full results
Most relevant research papers on this topic